Vor Biopharma Inc. (NYSE:VOR) Receives Consensus Recommendation of “Buy” from Brokerages

Vor Biopharma Inc. (NYSE:VOR) has been given an average rating of “Buy” by the seven ratings firms that are currently covering the stock, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $11.36.

A number of equities analysts have issued reports on the stock. Barclays reduced their price target on shares of Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating for the company in a research report on Wednesday, August 14th. Robert W. Baird decreased their target price on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating for the company in a research report on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and set a $12.00 price target on shares of Vor Biopharma in a research report on Friday, September 6th. Wedbush reissued an “outperform” rating and issued a $11.00 price objective on shares of Vor Biopharma in a report on Friday, November 8th. Finally, HC Wainwright restated a “buy” rating and issued a $17.50 target price on shares of Vor Biopharma in a research note on Friday, November 8th.

Vor Biopharma Price Performance

NYSE VOR opened at $0.79 on Friday. The stock’s fifty day moving average price is $0.77 and its 200 day moving average price is $0.99. Vor Biopharma has a 1 year low of $0.63 and a 1 year high of $3.14. The company has a market cap of $54.35 million, a price-to-earnings ratio of -0.48 and a beta of -0.40.

Vor Biopharma (NYSE:VOR) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.40). Research analysts expect that Vor Biopharma will post -1.55 earnings per share for the current year.

Institutional Investors Weigh In On Vor Biopharma

Hedge funds have recently modified their holdings of the company. Hsbc Holdings PLC increased its stake in shares of Vor Biopharma by 177.0% in the 2nd quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock valued at $51,000 after purchasing an additional 31,333 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Vor Biopharma during the 2nd quarter worth approximately $53,000. Rosalind Advisors Inc. purchased a new position in shares of Vor Biopharma during the 3rd quarter valued at approximately $54,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Vor Biopharma in the 2nd quarter valued at $63,000. Finally, Acadian Asset Management LLC increased its holdings in Vor Biopharma by 51.4% in the 2nd quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock worth $79,000 after acquiring an additional 27,597 shares in the last quarter. 97.29% of the stock is owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.